The FDA is reporting a shortage in certain strengths and presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).
Specifically, Pfizer will be sending weekly shipments of Solu-Medrol Sterile Powder for Injection 40mg/single-use vial and 125mg/single-use vial ACT-O-Vial System while the product is in shortage, with full recovery projected at the beginning of July 2016. Other strengths and presentations of Solu-Medrol are currently available.
Fresenius Kabi is reporting that Methylprednisolone sodium succinate for injection 40mg single-dose vial and 125mg single-dose vial are both on backorder with the next release of product expected in late April 2016; the 1g single-dose vial is currently available.
Solu-Medrol is indicated for the treatment of steroid-responsive disorders when oral therapy may not be feasible.
For more information visit FDA.gov.